Medications in PregnancyNCT06925672
Knowledge, Attitude and Perception of Pregnant Women Regarding Medications
An observational study of Medications in Pregnancy, run by Rania Hassan Mostafa at 1 site in Egypt.
Trial summary
The goal of this observational study is to learn about the pregnant women's knowledge, attitude, and perception regarding the use of medications in pregnancy. The main question it aims to answer is: What is the present knowledge, attitude, and perception of pregnant women regarding medication use? Participants… Read more about this study
- Who is it for?
- Ages 18 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Medications in Pregnancy
- What is being tested?
- Questionnaire
- How many people
- 150 participants
- Where
- 1 siteEgypt
- Study dates
- 1 May 2025to 13 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Pregnant women who attend the Ain shams University Maternity Hospital for their routine antenatal check-up visits
Who may be able to join
- Pregnant women attending the Ain shams University Maternity Hospital
Who cannot join
- Pregnant ladies refusing to participate in study.
- Pregnant ladies needing immediate transport to emergency department.
- Pregnant ladies needing immediate intervention.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessment Of Knowledge, Attitude and Perception of Pregnant Women Regarding Medications Use
The goal of this observational study is to learn about the pregnant women's knowledge, attitude, and perception regarding the use of medications in pregnancy. The main question it aims to answer is:
What is the present knowledge, attitude, and perception of pregnant women regarding medication use?
Participants (pregnant women) already attending the antenatal clinic for routine follow-up will answer survey questions about their knowledge, attitude, and beliefs about medication use and restriction during pregnancy, as well as the source of their information.
Read the detailed description
This is a descriptive cross-sectional study (survey) that will be held at Ain shams University Maternity Hospital.
The protocol approval will be sought from the ethical committee of department of Obstetrics and Gynecology, Ain Shams University.
- Data collection (the questionnaire): The study will use anonymous questionnaire; based upon previous similar studies.
The questionnaire comprises closed-ended questions categorized into four sections, along with fifth section consisting of statements pertaining to respondents' beliefs:
- Section A (10 items) will contain information about the participant's socio-demographic and health related characteristics.
- Section B (7 items) will assess their knowledge about medication use and restriction, during pregnancy.
- Section C (4 items) will assess their attitude about medication. D. Section D (4 items) will assess the source of their information. E. Section E (9 statements) will assess their beliefs about medications use during pregnancy.
This questionnaire will be presented in its Arabic version and pre-tested on 15 pregnant women to evaluate the construct and content validity, as well as to determine if any modifications to wording are necessary. These participants will not be included in the final analysis.
The questionnaire will be distributed to pregnant women who attend the hospital for their routine antenatal check-up visits. In instances where women are unable to read or write, the principal investigator and attending house officer in the unit will provide assistance in reading and explaining the questions to facilitate the completion of the questionnaire.
- Data will be collected and recorded.
- Statistical analysis will be done accordingly.
- Conditions
- Medications in Pregnancy
- Being tested
- Questionnaire
- Keywords
- pregnancy, medication, attitude, perception, knowledge, teratogenic
- Medical subject headings
- Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
QuestionnaireOther
Also called survey
This is an anonymous questionnaire; based upon previous similar studies.
The questionnaire comprises closed-ended questions categorized into four sections, along with fifth section consisting of statements pertaining to respondents' beliefs:
- Section A (10 items) will contain information about the participant's socio-demographic and health related characteristics.
- Section B (7 items) will assess their knowledge about medication use and restriction, during pregnancy.
- Section C (4 items) will assess their attitude about medication. D. Section D (4 items) will assess the source of their information. E. Section E (9 statements) will assess their beliefs about medications use during pregnancy.
This questionnaire will be presented in its Arabic version.
| Study group | Role | What they receive |
|---|---|---|
| Pregnant women | Pregnant women attending the Ain shams University Maternity Hospital Receives: Other: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Knowledge of pregnant women regarding medication use and restriction in pregnancy.
Degree of knowledge (information) that the pregnant women have about medication use and restriction during pregnancy, as well as the source of their information, as assessed by answering the questions in sections B and D in the questionnaire.
Measured: Once at recruitment
Secondary outcomes (2)
Attitude of pregnant women regarding medication use
The attitudes of the pregnant women towards medication use during pregnancy, as assessed by answering the questions in section C in the questionnaire.
Measured: Once at recruitment
Perception and beliefs of pregnant women regarding medication use and restriction
The beliefs of the pregnant women regarding medication use during pregnancy, as assessed by answering the questions in section E in the questionnaire.
Measured: Once at recruitment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2025
- Study start1 May 2025
- Primary completion12 Oct 2025
- Study completion13 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Medications in PregnancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rania Hassan Mostafa
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Rania Hassan Mostafa, Ain Shams Maternity Hospital
- Investigators
- Ahmed Khairy, MD, Study chair, Faculty of Medicine, Ain Shams University.Ebtihal M Eltaieb, MD, Study director, Faculty of Medicine, Ain Shams University.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06925672
- Sponsor's protocol ID
- FMASU MS 185/2025
- Status last verified
- Oct 2026
- First submitted
- 7 Apr 2025
- Last updated
- 27 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The study protocol, the questionnaire used, and the analytic code will be made available on OSF platform.
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment Of Knowledge, Attitude and Perception of Pregnant Women Regarding Medications Use
- ClinicalTrials.gov ID
- NCT06925672
- Acronym / sponsor ID
- FMASU MS 185/2025
- Conditions
- Medications in Pregnancy
- Keywords
- pregnancy, medication, attitude, perception, knowledge, teratogenic
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Rania Hassan MostafaUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- 12 Oct 2025 (actual)
- Study completion
- 13 Aug 2026 (actual)
- First posted
- 13 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the pregnant women's knowledge, attitude, and perception regarding the use of medications in pregnancy. The main question it aims to answer is:
What is the present knowledge, attitude, and perception of pregnant women regarding medication use?
Participants (pregnant women) already attending the antenatal clinic for routine follow-up will answer survey questions about their knowledge, attitude, and beliefs about medication use and restriction during pregnancy, as well as the source of their information.
Detailed description
This is a descriptive cross-sectional study (survey) that will be held at Ain shams University Maternity Hospital.
The protocol approval will be sought from the ethical committee of department of Obstetrics and Gynecology, Ain Shams University.
- Data collection (the questionnaire): The study will use anonymous questionnaire; based upon previous similar studies.
The questionnaire comprises closed-ended questions categorized into four sections, along with fifth section consisting of statements pertaining to respondents' beliefs:
- Section A (10 items) will contain information about the participant's socio-demographic and health related characteristics.
- Section B (7 items) will assess their knowledge about medication use and restriction, during pregnancy.
- Section C (4 items) will assess their attitude about medication. D. Section D (4 items) will assess the source of their information. E. Section E (9 statements) will assess their beliefs about medications use during pregnancy.
This questionnaire will be presented in its Arabic version and pre-tested on 15 pregnant women to evaluate the construct and content validity, as well as to determine if any modifications to wording are necessary. These participants will not be included in the final analysis.
The questionnaire will be distributed to pregnant women who attend the hospital for their routine antenatal check-up visits. In instances where women are unable to read or write, the principal investigator and attending house officer in the unit will provide assistance in reading and explaining the questions to facilitate the completion of the questionnaire.
- Data will be collected and recorded.
- Statistical analysis will be done accordingly.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pregnant women | – | Other: QuestionnairePregnant women attending the Ain shams University Maternity Hospital |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Pregnant women who attend the Ain shams University Maternity Hospital for their routine antenatal check-up visits
Key inclusion criteria (1 listed)
- Pregnant women attending the Ain shams University Maternity Hospital
Key exclusion criteria (3 listed)
- Pregnant ladies refusing to participate in study.
- Pregnant ladies needing immediate transport to emergency department.
- Pregnant ladies needing immediate intervention.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| QuestionnaireAlso: surveyThis is an anonymous questionnaire; based upon previous similar studies. The questionnaire comprises closed-ended questions categorized into four sections, along with fifth section consisting of statements pertaining to respondents' beliefs: A. Section A (10 items) will contain information about the participant's socio-demographic and health related characteristics. B. Section B (7 items) will assess their knowledge about medication use and restriction, during pregnancy. C. Section C (4 items) will assess their attitude about medication. D. Section D (4 items) will assess the source of their information. E. Section E (9 statements) will assess their beliefs about medications use during pregnancy. This questionnaire will be presented in its Arabic version. | Other | Pregnant women |
Primary outcome
Knowledge of pregnant women regarding medication use and restriction in pregnancy.
Time frame: Once at recruitment
Degree of knowledge (information) that the pregnant women have about medication use and restriction during pregnancy, as well as the source of their information, as assessed by answering the questions in sections B and D in the questionnaire.
2 secondary outcomes
Attitude of pregnant women regarding medication use
Time frame: Once at recruitment
Perception and beliefs of pregnant women regarding medication use and restriction
Time frame: Once at recruitment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Individual participant dataSharing planned: Yes. The study protocol, the questionnaire used, and the analytic code will be made available on OSF platform.
Related trials for Medications in Pregnancy
Active, not recruitingPhase 2/3
Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome
Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic Syndrome
RecruitingPhase 3
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Epithelial Ovarian Cancer
RecruitingPhase 3
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Non-muscle Invasive Bladder Cancer
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ahmed Khairy, MD study chair
Faculty of Medicine, Ain Shams University.
Ebtihal M Eltaieb, MD study director
Faculty of Medicine, Ain Shams University.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Medications in Pregnancy, run by Rania Hassan Mostafa at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Knowledge of pregnant women regarding medication use and restriction in pregnancy. (time frame: Once at recruitment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.